The states with the highest rates of HIV diagnoses in 2022 included Georgia, Louisiana, and Florida. However, the states with the highest number of people with HIV were Texas, California, and Florida. In Texas, there were around 4,896 people diagnosed with HIV. HIV/AIDS diagnoses In 2022, there were an estimated 38,043 new HIV diagnoses in the United States, a slight increase compared to the year before. Men account for the majority of these new diagnoses. There are currently around 1.2 million people living with HIV in the United States. Deaths from HIV The death rate from HIV has decreased significantly over the past few decades. In 2023, there were only 1.3 deaths from HIV per 100,000 population, the lowest rate since the epidemic began. However, the death rate varies greatly depending on race or ethnicity, with the death rate from HIV for African Americans reaching 19.2 per 100,000 population in 2022, compared to just three deaths per 100,000 among the white population.

In 2022, the District of Columbia had the highest HIV disease death rate among all U.S. states where 6.2 out of 100,000 inhabitants died due to HIV in 2022. This statistic shows the U.S. states with the highest HIV disease death rates in 2022.

United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.500 % in 2014. This stayed constant from the previous number of 0.500 % for 2013. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.500 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.500 % in 2014 and a record low of 0.500 % in 2014. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.; ; UNAIDS estimates.; Weighted Average;

United States US: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.110 Ratio in 2019. This stayed constant from the previous number of 0.110 Ratio for 2018. United States US: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.120 Ratio from Dec 2010 (Median) to 2019, with 10 observations. The data reached an all-time high of 0.130 Ratio in 2012 and a record low of 0.110 Ratio in 2019. United States US: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

These data were reported to the NYC DOHMH by March 31, 2021

This dataset includes data on new diagnoses of HIV and AIDS in NYC for the calendar years 2016 through 2020. Reported cases and case rates (per 100,000 population) are stratified by United Hospital Fund (UHF) neighborhood, sex, and race/ethnicity.

In 2023, Black or African Americans had the highest rates of HIV diagnoses among males in the United States. In that year, among all men, 19 per 100,000 were diagnosed with HIV. This statistic displays the rate of HIV diagnoses among males in the U.S. in 2023, by race and ethnicity (per 100,000 population).

The average for 2022 based on 12 countries was 0.67 percent. The highest value was in Suriname: 1.6 percent and the lowest value was in Argentina: 0.4 percent. The indicator is available from 1990 to 2022. Below is a chart for all countries where data are available.

United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data was reported at 0.020 % in 2014. This stayed constant from the previous number of 0.020 % for 2013. United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data is updated yearly, averaging 0.030 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.030 % in 2012 and a record low of 0.020 % in 2014. United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Number of new HIV infections among uninfected populations ages 15-49 expressed per 100 uninfected population in the year before the period.; ; UNAIDS estimates.; Weighted Average;

BackgroundIn the generalised epidemics of sub-Saharan Africa (SSA), human immunodeficiency virus (HIV) prevalence shows patterns of clustered micro-epidemics. We mapped and characterised these high-prevalence areas for young adults (15–29 years of age), as a proxy for areas with high levels of transmission, for 7 countries in Eastern and Southern Africa: Kenya, Malawi, Mozambique, Tanzania, Uganda, Zambia, and Zimbabwe.Methods and findingsWe used geolocated survey data from the most recent United States Agency for International Development (USAID) demographic and health surveys (DHSs) and AIDS indicator surveys (AISs) (collected between 2008–2009 and 2015–2016), which included about 113,000 adults—of which there were about 53,000 young adults (27,000 women, 28,000 men)—from over 3,500 sample locations. First, ordinary kriging was applied to predict HIV prevalence at unmeasured locations. Second, we explored to what extent behavioural, socioeconomic, and environmental factors explain HIV prevalence at the individual- and sample-location level, by developing a series of multilevel multivariable logistic regression models and geospatially visualising unexplained model heterogeneity. National-level HIV prevalence for young adults ranged from 2.2% in Tanzania to 7.7% in Mozambique. However, at the subnational level, we found areas with prevalence among young adults as high as 11% or 15% alternating with areas with prevalence between 0% and 2%, suggesting the existence of areas with high levels of transmission Overall, 15.6% of heterogeneity could be explained by an interplay of known behavioural, socioeconomic, and environmental factors. Maps of the interpolated random effect estimates show that environmental variables, representing indicators of economic activity, were most powerful in explaining high-prevalence areas. Main study limitations were the inability to infer causality due to the cross-sectional nature of the surveys and the likely under-sampling of key populations in the surveys.ConclusionsWe found that, among young adults, micro-epidemics of relatively high HIV prevalence alternate with areas of very low prevalence, clearly illustrating the existence of areas with high levels of transmission. These areas are partially characterised by high economic activity, relatively high socioeconomic status, and risky sexual behaviour. Localised HIV prevention interventions specifically tailored to the populations at risk will be essential to curb transmission. More fine-scale geospatial mapping of key populations,—such as sex workers and migrant populations—could help us further understand the drivers of these areas with high levels of transmission and help us determine how they fuel the generalised epidemics in SSA.

Association between US ED characteristics and location in an HIV priority jurisdiction.

In 2023, the death rate from HIV was highest among African Americans, with around 18 deaths per 100,000 population. This statistic shows the death rate from HIV in the U.S. in 2023, by race and ethnicity, per 100,000 population.

The USA: Prevalence of HIV, percent of the population ages 15-49: The latest value from 2021 is 0.4 percent, unchanged from 0.4 percent in 2020. In comparison, the world average is 1.63 percent, based on data from 143 countries. Historically, the average for the USA from 2010 to 2021 is 0.4 percent. The minimum value, 0.4 percent, was reached in 2010 while the maximum of 0.4 percent was recorded in 2010.

This indicator provides information about the rate of persons living with HIV (persons per 100,000 population).Human immunodeficiency virus (HIV) infection remains a significant public health concern, with more than 59,000 Los Angeles County residents estimated to be currently living with HIV. Certain communities, such as low-income communities, communities of color, and sexual and gender minority communities, bear a disproportionate burden of this epidemic. The Ending the HIV Epidemic national initiative strives to eliminate the US HIV epidemic by 2030, focusing on four key strategies: Diagnose, Treat, Prevent, and Respond. Achieving this goal requires a collaborative effort involving cities, community organizations, faith-based institutions, healthcare professionals, and businesses. Together, they can create an environment that promotes prevention, reduces stigma, and empowers individuals to safeguard themselves and their partners from HIV. Stakeholders can advance health equity by focusing on the most affected communities and sub-populations.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

Drugs for HIV Market Outlook

The global Drugs for HIV market size was valued at approximately USD 30.5 billion in 2023 and is projected to reach around USD 42.7 billion by 2032, growing at a CAGR of 3.8% from 2024 to 2032. This market is primarily driven by the increasing prevalence of HIV infections globally, advancements in drug development, and supportive governmental and non-governmental initiatives aimed at combating the HIV epidemic.

One of the significant growth factors for the Drugs for HIV market is the rising awareness about HIV/AIDS and the importance of early diagnosis and treatment. Efforts by global health organizations, such as the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS), to promote awareness and preventive measures have significantly contributed to early diagnosis rates, thus driving the demand for antiretroviral therapy (ART). Moreover, the reduction in stigma associated with HIV/AIDS has encouraged more individuals to seek treatment, further bolstering market growth.

Another crucial factor contributing to the market's expansion is the continuous innovation in HIV drug development. The introduction of novel drug classes, combination therapies, and long-acting injectable formulations has improved the efficacy and convenience of HIV treatment regimens. These innovations not only enhance patient compliance but also reduce the risk of drug resistance, thereby improving treatment outcomes. Furthermore, the ongoing research and development (R&D) efforts to discover new therapeutic targets and the development of vaccines offer promising avenues for future market growth.

The supportive regulatory environment and favorable reimbursement policies in several regions also play a pivotal role in the growth of the Drugs for HIV market. Governments and healthcare systems in developed countries, as well as some developing nations, provide substantial funding and reimbursement for HIV treatment, making it more accessible to patients. Initiatives such as the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria have been instrumental in expanding access to HIV drugs, particularly in low- and middle-income countries.

Regionally, North America and Europe are expected to maintain a significant share of the market due to the high prevalence of HIV, advanced healthcare infrastructure, and robust R&D activities. The Asia Pacific region is anticipated to witness the highest growth rate, driven by increasing HIV cases, rising awareness, and improving healthcare facilities. Africa remains a critical focus area due to the high burden of HIV, with efforts being directed towards improving access to treatment and preventive measures.

Drug Class Analysis

Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Analysis

Nucleoside Reverse Transcriptase Inhibitors (NRTIs) form the backbone of most HIV treatment regimens. These drugs work by inhibiting the reverse transcriptase enzyme, which is crucial for viral replication. The effectiveness of NRTIs, combined with their relatively well-tolerated safety profiles, makes them a cornerstone of antiretroviral therapy (ART). The market for NRTIs is bolstered by the continuous development of newer drugs with improved efficacy and reduced side effects. Drugs such as tenofovir alafenamide and emtricitabine are widely used due to their potent antiviral activity and favorable safety profiles.

The demand for NRTIs is also driven by their inclusion in fixed-dose combination therapies, which simplify treatment regimens and enhance patient adherence. For instance, combination drugs like Truvada and Descovy, which contain NRTIs, are used both for treatment and as pre-exposure prophylaxis (PrEP) to prevent HIV infection. The market growth is further supported by ongoing research to develop next-generation NRTIs that can overcome resistance issues and provide better treatment outcomes.

Despite their widespread use, NRTIs face challenges such as the development of drug resistance and potential long-term side effects, including renal toxicity and bone density loss. To address these concerns, pharmaceutical companies are investing in the development of novel NRTIs with improved safety profiles. Additionally, the use of pharmacogenomics to tailor NRTI therapy based on individual genetic profiles is an emerging trend that holds promise for personalized medicine in HIV treatment.

In terms of market dy

Characteristics of US EDs stratified by priority jurisdiction designation and teaching hospital affiliation.

Note. Data include persons with diagnosed HIV infection regardless of stage of disease at diagnosis. HIV diagnosis data were statistically adjusted for missing transmission category, but not for reporting delays or incomplete reporting. All results for each outcome of interest in the models are based on controlling for all other variables.MSM, men who reported ever having had sexual contact with other men.CI, confidence interval.aBlack non-MSM is the reference group.bThe prevalence odds is defined as (#MSM+1)/(#non-MSM+1), where adding 1 to both the numerator and the denominator avoids the prevalence odds undefined when there are no diagnosed HIV infections among black non-MSM. PORs>1 indicates that among black males, as the proportion of a SDH variable of interest increases, the probability of black MSM diagnosed with HIV is higher compared to black non-MSM.Prevalence odds ratiosa of HIV infection diagnosis for black/African American MSM vs. non-MSM, by selected census tract-level social determinants of health (SDH), 2005–2009—17 areas.

This horizontal bar chart displays incidence of HIV (per 1,000 uninfected population) by ISO 3 country code using the aggregation average, weighted by population in Central America. The data is about countries per year.

This horizontal bar chart displays incidence of HIV (per 1,000 uninfected population) by demonym using the aggregation average, weighted by population in South America. The data is filtered where the date is 2021. The data is about countries per year.

HIV-1 Testing Market Outlook

The global HIV-1 testing market size was valued at approximately USD 2.5 billion in 2023 and is projected to reach USD 4.8 billion by 2032, exhibiting a CAGR of 7.2% over the forecast period. The market is primarily driven by the increasing prevalence of HIV/AIDS worldwide, advancements in diagnostic technologies, and growing awareness about early diagnosis and treatment. The significant rise in the number of government initiatives and funding aimed at combating HIV/AIDS is also expected to propel the market growth.

One of the key growth factors in the HIV-1 testing market is the continuous increase in HIV prevalence globally. According to UNAIDS, around 37.7 million people were living with HIV worldwide in 2020. This substantial patient pool necessitates the need for effective and accessible diagnostic tools. Governments and healthcare organizations are increasingly investing in initiatives to enhance HIV testing services, which in turn is expected to drive market growth. Additionally, the growing awareness and educational campaigns about HIV/AIDS and its early detection are contributing to the increased adoption of HIV-1 testing.

Technological advancements in diagnostic tools represent another crucial driver for the HIV-1 testing market. The development of highly sensitive and specific tests, such as nucleic acid tests (NAT) and fourth-generation antigen/antibody combination assays, has significantly improved the accuracy and reliability of HIV diagnosis. These advanced testing methods can detect the virus at an earlier stage, thereby facilitating timely intervention and treatment. The integration of point-of-care testing (POCT) devices has further enhanced the accessibility and convenience of HIV testing, particularly in resource-limited settings.

The increase in government initiatives and funding directed towards HIV/AIDS research and prevention is also playing a pivotal role in the market's growth. Various international agencies and governments are actively involved in efforts to reduce the transmission of HIV and improve the quality of life for those affected. For instance, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria are significant contributors in this domain. These initiatives are not only focused on providing antiretroviral treatments but also emphasize the importance of regular and early testing, thereby boosting the market for HIV-1 diagnostic tests.

Sleeping Sickness Testing is another critical area of focus in the realm of infectious disease diagnostics. Sleeping sickness, or Human African Trypanosomiasis, is a parasitic disease that poses significant health challenges in certain regions of Africa. The development and deployment of effective testing methods for sleeping sickness are crucial for early detection and treatment, which can prevent severe health complications and reduce mortality rates. Advances in diagnostic technologies, similar to those seen in the HIV-1 testing market, are being leveraged to improve the sensitivity and specificity of sleeping sickness tests. These innovations are vital for enhancing disease management and supporting global health initiatives aimed at eradicating neglected tropical diseases.

Regionally, North America holds a significant share in the HIV-1 testing market, driven by the high prevalence of HIV, advanced healthcare infrastructure, and robust government initiatives. Europe follows closely, with increasing awareness and improved healthcare facilities. The Asia Pacific region is expected to witness the fastest growth during the forecast period, fueled by rising HIV cases, increasing healthcare expenditure, and growing public health campaigns. Latin America and the Middle East & Africa are also anticipated to contribute to market growth, owing to the expanding healthcare services and international support for combating HIV/AIDS.

Test Type Analysis

The HIV-1 testing market can be segmented by test type into antibody tests, antigen tests, nucleic acid tests (NAT), and others. Antibody tests are among the most commonly used HIV diagnostic tools, primarily due to their high sensitivity and specificity. These tests detect antibodies produced by the body in response to HIV infection and are widely used in both clinical and non-clinical settings. The ease of use and cost-effectiveness of antibody tests make them a popular choice in resource-limited settings, contributing

United States US: Children: 0-14 Living with HIV data was reported at 2,500.000 Person in 2019. This records a decrease from the previous number of 2,800.000 Person for 2018. United States US: Children: 0-14 Living with HIV data is updated yearly, averaging 3,700.000 Person from Dec 2010 (Median) to 2019, with 10 observations. The data reached an all-time high of 4,700.000 Person in 2010 and a record low of 2,500.000 Person in 2019. United States US: Children: 0-14 Living with HIV data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Social: Health Statistics. Children living with HIV refers to the number of children ages 0-14 who are infected with HIV.;UNAIDS estimates.;;